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In the kidney, glucose in glomerular filtrate is reabsorbed primarily by sodium-glucose
cotransporters 1 (SGLT1) and 2 (SGLT2) along the proximal tubules. SGLT2 has been
characterized as a high capacity, low affinity pathway responsible for reabsorption of the
majority of filtered glucose in the early part of proximal tubules, and SGLT1 reabsorbs
the residual glucose in the distal part. Inhibition of SGLT2 is a viable mechanism for
removing glucose from the body and improving glycemic control in patients with diabetes.
Despite demonstrating high levels (in excess of 80%) of inhibition of glucose transport by
SGLT2 in vitro, potent SGLT2 inhibitors, e.g., dapagliflozin and canagliflozin, inhibit renal
glucose reabsorption by only 30–50% in clinical studies. Hypotheses for this apparent
paradox are mostly focused on the compensatory effect of SGLT1. The paradox has
been explained and the role of SGLT1 demonstrated in the mouse, but direct data in
humans are lacking. To further explore the roles of SGLT1/2 in renal glucose reabsorption
in humans, we developed a systems pharmacology model with emphasis on SGLT1/2
mediated glucose reabsorption and the effects of SGLT2 inhibition. The model was
calibrated using robust clinical data in the absence or presence of dapagliflozin (DeFronzo
et al., 2013), and evaluated against clinical data from the literature (Mogensen, 1971;
Wolf et al., 2009; Polidori et al., 2013). The model adequately described all four data
sets. Simulations using the model clarified the operating characteristics of SGLT1/2 in
humans in the healthy and diabetic state with or without SGLT2 inhibition. The modeling
and simulations support our proposition that the apparent moderate, 30–50% inhibition
of renal glucose reabsorption observed with potent SGLT2 inhibitors is a combined result
of two physiological determinants: SGLT1 compensation and residual SGLT2 activity. This
model will enable in silico inferences and predictions related to SGLT1/2 modulation.
Keywords: systems pharmacology model, SGLT, dapagliflozin, renal glucose reabsorption, glucosuria, diabetes
mellitus
INTRODUCTION
In the kidney, plasma glucose is continuously filtered by glomeruli
and reabsorbed along the proximal tubules. Under normal
physiological conditions, the reabsorption is almost complete.
The reabsorption is mediated primarily by two sodium-glucose
cotransporters (SGLTs), SGLT1 and SGLT2. In the kidney, SGLT2
is located in the early part (S1/S2 segments) of the proximal
tubules, and is recognized as a low affinity, high capacity path-
way for renal glucose reabsorption. SGLT1, on the other hand, is
located in the distal part (S3 segment) of the proximal tubules,
and is characterized as a high affinity, low capacity pathway
(Wright, 2001; Mather and Pollock, 2011). SGLT2 is believed
responsible for 80–90% of renal glucose reabsorption, and SGLT1
for the rest (10–20%) in healthy humans under normal physiolog-
ical conditions (DeFronzo et al., 2012). SGLT2 has been identified
as a viable target for improving glycemic control in diabetes.
Two potent and selective SGLT2 inhibitors, dapagliflozin and
canagliflozin, have been approved by many regulatory agencies
for treating type 2 diabetes mellitus (T2DM).
Given the overwhelming contribution (>80%) of SGLT2 to
renal glucose reabsorption, it has been expected that SGLT2
inhibitors, at sufficient exposures, would reduce renal glu-
cose reabsorption by over 80%. This expectation, however,
appeared to be contradicted by the clinical observations that
only 30–50% of inhibition in glucose reabsorption was achieved
with dapagliflozin and canagliflozin (Komoroski et al., 2009a;
Devineni et al., 2013; Washburn and Poucher, 2013). To explain
this apparent contradiction, several hypotheses, from peculiar
pharmacokinetics of an inhibitor in the kidney (Liu et al., 2012)
to SGLT1 compensation (Haddish-Berhane et al., 2010; Maurer
et al., 2011; Abdul-Ghani et al., 2013), have been proposed. These
hypotheses are yet to be tested.
www.frontiersin.org December 2014 | Volume 5 | Article 274 | 1
Lu et al. Characterize SGLTs in renal glucose reabsorption
Recently, Hummel et al. (2011) used a quantitative in vitro
electrophysiological study to generate hypotheses about the rela-
tive contributions of human SGLTs to renal glucose reabsorption.
Hummel et al. found that the two human transporters have sim-
ilar apparent affinity for D-glucose (5mM for hSGLT2 vs. 2mM
for hSGLT1), and inferred that the capacity of hSGLT1 for renal
glucose reabsorption may be over 50% of hSGLT2 under normal
conditions in humans. As such, the difference in the contribution
to renal glucose reabsorption between the two cotransporters may
be less profound than previously perceived.
Despite a large body of research in SGLTs and renal glucose
reabsorption, the quantitative understanding of the characteris-
tics of these cotransporters in humans remains limited (Vallon,
2011). Assessments in this regard have largely relied on frag-
ments of data, insufficient to account for all key variables (e.g.,
SGLTs activities, plasma glucose levels, pharmacokinetic profiles
of SGLTs inhibitors), and empirical, static mathematical models
that do not account for the dynamic processes of renal glucose fil-
tration, reabsorption, and transfer along tubular lumen over time.
Consequently, a quantitative, holistic characterization has not yet
been formulated.
Systems pharmacology modeling is a powerful tool for data
and knowledge integration and hypothesis testing, and for pro-
viding quantitative understanding of a pharmacological target or
pathway and insights into “what-if” scenarios that may not be
feasibly obtained experimentally. For SGLTs-mediated renal glu-
cose reabsorption, Yamaguchi et al. reported simplified systems
pharmacology models in mice (Yamaguchi et al., 2012) and rats
(Yamaguchi et al., 2011), and Haddish-Berhane et al. (2010) pre-
sented a conference poster on a minimal systems pharmacology
model in humans with limited evaluation against clinical data on
dapagliflozin (Komoroski et al., 2009a).
This report presents a systems pharmacology model that was
developed based on renal physiology and a robust clinical data
set, with emphasis on SGLTs-mediated glucose reabsorption in
the proximal tubules. The model was evaluated against several
external clinical data sets. It is anticipated that the model will be
valuable in:
(1) Quantitatively evaluating the relative contributions of SGLT1
and SGLT2 to renal glucose reabsorption under various glu-
cose load conditions in humans;
(2) Explaining the apparently contradictory clinical observation
that potent SGLT2 inhibitors only inhibit 30–50% of renal
glucose reabsorption;
(3) Mapping genetic mutations of renal SGLT2 to its in vivo
activity and urinary glucose excretion (UGE); and
(4) Predicting the effect of SGLT2 inhibition on glycemic con-
trol in diabetes mellitus where clinical data remain scarce,
e.g., elderly and pediatric patients, and patients with type 1
diabetes mellitus (Lu et al., 2014).
MATERIALS AND METHODS
STUDIES AND DATA SETS
The studies and data sets used for model calibration and evalua-
tion are listed in Table 1. For more details, the reader is referred
to the original reports.
The DeFronzo et al. (2013), Polidori et al. (2013) and Wolf
et al. (2009) studies employed stepped hyperglycemic clamp
(SHC) procedures, and the Mogensen study (1971) was con-
ducted at fixed, elevated plasma glucose levels. The clinical
approach of artificially maintaining a constant plasma glucose
concentration allowed us to ignore the potential impacts of renal
glucose reabsorption on plasma glucose concentration, hence
simplifying the process of model development. Simulations using
the systems pharmacology model with fixed glucose levels will
provide “clean” illustrations of SGLTs operating characteristics. A
more comprehensive model integrating renal glucose reabsorp-
tion and glucose-insulin homeostasis will be reported elsewhere
(Lu et al., 2014).
The mean data from each study were used for model cali-
bration or evaluation. The data in DeFronzo et al. (2013) were
available from an internal database owned by Bristol-Myers
Squibb/AstraZeneca. We excluded from analysis those data points
where the actual plasma glucose level deviated 25% or more from
the corresponding group means. These data points appeared at
the steps with target glucose level ≥450mg/dL, and represented
only 17% of total data points at those steps. This exclusion should
abolish potential undue influences of excessive variability in the
data on parameter estimation.
MODEL STRUCTURE
The model structure, shown in Figure 1, was developed based
on the renal physiology and pharmacological understanding of
SGLTs inhibition. The model describes the disposition of glu-
cose as well as SGLTs inhibitors, if applicable, with emphasis
on glomerular filtration and tubular reabsorption. The proximal
convoluted tubules (PCT) were divided equally into six sequen-
tial sub-segments (PCT1-6), and the proximal straight tubules
(PST) were divided equally into three sub-segments (PST1-3).
The division allowed a more accurate description of the luminal
glucose concentration as the filtrate progresses through tubular
segments and the amount of UGE over time. The number of
sub-segments was chosen to achieve an approximate agreement
between predicted and observed UGE in a healthy subject under
normal conditions. The distal tubules were not included due to
their irrelevance to glucose reabsorption. The glomerular filtrate
flowed from PCT1 through PST3 and drained into the urinary
bladder. A urine compartment was added for collecting urine and
urinary glucose.
Along the proximal tubules, filtered glucose was continuously
reabsorbed. It was assumed that the absorption was mediated
by SGLT2 in the PCT (PCT1-6) and by SGLT1 in the PST
(PST1-3). The maximum reabsorption rate of SGLT2 (Vmax2)
was uniformly distributed among the PCT1-6 sub-segments, and
likewise for the Vmax of SGLT1 (Vmax1) among the PST1-3 sub-
segments. In each sub-segment, glucose was reabsorbed via a
Michaelis-Menten process as Equation (1):
Rj = Vmax,j × Cglu,j
Km + Cglu,j (1)
where the subscript j is an index for a tubular sub-segment,
and for a given sub-segment, R is the glucose reabsorption rate
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Table 1 | Studies and data sets used for model calibration and evaluation.
Study Subjects Study procedure Data pertinent to modeling Use
DeFronzo et al., 2013 Healthy (N = 12),
T2DM (N = 12)
SHC at baseline and after 7 daily doses of
10mg dapagliflozin treatment; target
plasma glucose level 100, 150, 200, 250,
300, 350, 400, 450, 500, and 550mg/dL.
Dapagliflozin plasma concentration time
course after the last dose; actual plasma
glucose and iohexol concentrations, urine
volume, urine glucose and iohexol
concentrations at each step.
Raw data available from BMS internal
database.
Model calibration
Polidori et al., 2013 T2DM (N = 28) SHC at baseline and after 8 daily doses of
100mg canagliflozin treatment; target
blood glucose level 126, 171, 216, 261,
and 306mg/dL at baseline and 72, 117,
162, 207, and 252mg/dL after treatment.
Canagliflozin plasma concentration time
course in Devineni et al. (2013); Creatinine
clearance, actual blood glucose, and UGE
rate in Polidori et al. (2013).
Model evaluation
Mogensen, 1971 Healthy (N = 9),
Diabetics (N = 10)
Plasma glucose escalated to over
650mg/dL via glucose infusion.
GFR, plasma glucose concentration, and
UGE rate in Mogensen (1971).
Model evaluation
Wolf et al., 2009 T2DM (N = 22) SHC; target blood glucose level 140, 160,
180, 200, 220, 240mg/dL.
GFR, actual blood glucose level, and
tubular glucose reabsorption rate in Wolf
et al. (2009).
Model evaluation
FIGURE 1 | Structure of the systems pharmacology model for describing renal glucose reabsorption and the inhibitory effect of an SGLTs inhibitor.
PCT1-6: sub-segments 1–6 of proximal convoluted tubules; PST1-3: sub-segments 1–3 of proximal straight tubules; UB, urinary bladder.
(mass/time), Km denotes glucose affinity for SGLT1 or SGLT2,
and Cglu represents luminal glucose concentration.
The mass of reabsorbed glucose was directed to another com-
partment (glucose reabsorbed) instead of the plasma glucose
compartment. This approach is appropriate for scenarios where
renal glucose recovery does not affect plasma glucose level, such
as: (1) experimental procedures that fix plasma glucose levels
(Mogensen, 1971;Wolf et al., 2009; DeFronzo et al., 2013; Polidori
et al., 2013), and (2) subjects with normal glucose tolerance who
can efficiently dispose the absorbed mass to maintain plasma
glucose constant at the fasting state.
In the case where an SGLTs inhibitor, e.g., dapagliflozin or
canagliflozin, was administered, the unbound portion of the
inhibitor in plasma was freely filtered via glomeruli. The inhibitor
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then traveled through the tubular sub-segments and the urinary
bladder, and was excreted to the urine compartment, similar
to glucose but without tubular reabsorption. Within each sub-
segment, the inhibitor competed with glucose for SGLT1/2, and
hence competitively inhibited glucose reabsorption. The reab-
sorption rate (R∗j ), with competitive inhibition of an inhibitor,
in a given sub-segment became:
R∗j =
Vmax,j × Cglu,j
Km ×
(
1 + Cdrug,jKi
)
+ Cglu,j
(2)
where Cdrug denotes luminal SGLTs inhibitor concentration, and
Ki is the affinity of the inhibitor to SGLTs. [See Supplementary
Materials for further expansion of Equations (1) and (2)].
To obtain a similar time course of plasma concentration of
canagliflozin with the dosing regimen (100mg QD for 8 days)
described in Polidori et al. (2013), a two-compartment pharma-
cokinetic (PK) model was developed based on the mean PK data
reported (Devineni et al., 2013). For dapagliflozin, observedmean
PK after 10mg, QD, for 7 days was reported in DeFronzo et al.
(2013). Interpolation of the observed dapagliflozin PK provided
an input into the plasma inhibitor compartment (Figure 1) to
allow description of dapagliflozin inhibition of tubular glucose
reabsorption.
MODEL PARAMETERS AND CALIBRATION
The physiological parameters, such as volumes, flow rates, glu-
cose affinity for SGLTs (Km), and glucose reabsorption capacities
(Vmax) are listed in Table 2, and SGLT2 inhibitor physicochemi-
cal parameters and binding affinity for SGLTs (Ki) are in Table 3.
Most of the parameters were from the literature, measured in each
of the respective studies, or based on reasonable assumptions,
except for Vmax, Km, and Ki, whose values were calibrated. For
parameter calibration, literature values were taken as the starting
points (see Tables 2, 3), and then fine-tuned to allow the model
predictions to be consistent with the mean UGE data in DeFronzo
et al. (2013). Because a satisfactory agreement between the pre-
dictions and the observations of UGE could not be achieved over
the entire plasma glucose range of 100–550mg/dL, the calibra-
tion was focused on the data in the clinically relevant range,
100–400mg/dL. In the end, only the set of calibrated values
were considered physiologically plausible and accepted if it ade-
quately described the DeFronzo et al. (2013) as well as the other
three data sets (Mogensen, 1971; Wolf et al., 2009; Polidori et al.,
2013).
The potential influences of diabetes and SGLT2 inhibition on
the parameters to be calibrated were considered during param-
eterization. Renal SGLTs expression and activity may change
in response to SGLT2 inhibition and/or diabetes. In the wild-
type mouse, SGLT2 protein expression was enhanced with the
treatment of empagliflozin, a selective SGLT2 inhibitor, with-
out upregulation of mRNA (Vallon et al., 2014). In the diabetic
state, the expressions of SGLT2 mRNA and protein have been
found upregulated significantly relative to the respective con-
trols in genetically modified mice (Vallon et al., 2014), diabetic
rats, (Freitas et al., 2008; Tabatabai et al., 2009), and humans
(Rahmoune et al., 2005). For renal SGLT1, however, the response
is more diverse, with increased, unchanged, or reduced expression
and/or activity observed in animals (Vallon and Thomson, 2012;
Vallon et al., 2014). It is challenging to incorporate these potential
changes in SGLT activity in the model for two reasons: (i) limited
quantitative understanding in humans regarding these changes,
and (ii) adequate calibration of parameters for these changes is
not supported by available data. For simplification, therefore, the
Vmax1, Km, and Ki values were assumed consistent between the
healthy and diabetics, and Vmax2 was allowed to adjust between
the healthy and disease state. The Vmax2 in healthy subjects was
estimated as a proportion of that in diabetics, and the value of the
proportion was calibrated using the DeFronzo et al. (2013). The
potential impact of SGLT2 inhibition on Vmax, Km, and Ki values
was ignored.
Although Vmax in humans has generally been reported as the
sum of Vmax1 and Vmax2, with difficulty in separating the two
components, it is worth pointing out that in our study, quan-
titative separation of Vmax1 and Vmax2 was feasible without an
assumption of the value of Vmax1/Vmax2 ratio, because the cali-
bration data set (DeFronzo et al., 2013) encompassed scenarios
with and without perturbation of SGLT2 activity. Such a separa-
tion was achieved previously in rats with the aid of mathematical
modeling (Yamaguchi et al., 2011).
MODEL EVALUATION
Once it was calibrated using the DeFronzo et al. (2013), the model
was evaluated for its predictivity against three data sets from
different sources (Mogensen, 1971; Wolf et al., 2009; Polidori
et al., 2013). The parameters were held constant for the evalu-
ation unless they were study specific, in which case they were
adjusted per the study conditions as listed in Tables 1, 2. The Ki
values of canagliflozin, necessary for simulating the Polidori et al.,
conditions (Polidori et al., 2013), are listed in Table 3.
SIMULATIONS AND EXPLORATIONS
Renal glucose reabsorption and UGE vs. loss-of-function mutation
of SGLTs
Numerous mutations in SGLT1 (Martin et al., 1996; Lam et al.,
1999) and SGLT2 have been identified in humans (Santer et al.,
2003; Kleta et al., 2004; Calado et al., 2008; Yu et al., 2011).
The mutations in SGLT1 disrupt the trafficking of SGLT1 from
the endoplasmic reticulum to the plasma membrane (Lam et al.,
1999), and the mutations in SGLT2 reduce SGLT2 expression
in the apical side of PCT (Yu et al., 2011). These mutations
are likely to reduce the Vmax of these cotransporters. It is yet
to be clarified to what extent the function of SGLTs in the
kidney is affected by a given mutation. Simulations using our
systems pharmacology model can provide theoretical, quanti-
tative relationships between a reduction in Vmax and glucose
reabsorption or UGE in an otherwise healthy person. To enable
these simulations, the mean daily plasma glucose profile in the
healthy subjects from Freckmann et al. (2007) was used as an
input to the plasma glucose compartment of our model. The
quantitative SGLTs function-UGE relationships will be instru-
mental to mapping renal SGLTs genotypes to their apparent
functions.
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Table 2 | Physiological parameters.
Parameter Symbol (unit) Value Rationale and/or Reference
VOLUMES
Renal cortex volume VCTX (L) 0.216 Thelwall et al., 2011
Proximal tubules (PT) volume as a fraction of
renal cortex
VPTC 0.3 Moller and Skriver, 1985
PCT volume as a fraction of PT VPCTC 0.7 Assumed
PST volume as a fraction of PT VPSTC 1–VPCTC
Urinary bladder volume VX (L) 0.2 Brown et al., 2011
FLOW RATES
Glomerular filtration rate (GFR) GFR (L/h)
DeFronzo et al., healthy baseline 5.66–7.38 Measured using iohexol as a marker,
raw data from an internal database
owned by Bristol-Myers
Squibb/AstraZeneca
DeFronzo et al., healthy after dapagliflozin 5.19–7.41
DeFronzo et al., T2DM baseline 6.52–7.62
DeFronzo et al., T2DM after dapagliflozin 5.07–7.53
Healthy and diabetic subjects in other
studies
Various Mogensen, 1971; Wolf et al., 2009;
Polidori et al., 2013
Filtrate flow rate in tubular lumen KPCi (L/h) for PCT, where
i = 1–6;
KPSj (L/h) for PST, where
j = 1–3
From 0.926 × GFR to
0.333 × GFR with
decrements of 0.074 ×
GFR for PCT1 to PST3
Calculated based on (1) 2/3 of filtered
water is reabsorbed by the end of PT
(Koeppen and Stanton, 2013), and (2)
the assumption that the water
reabsorption rate is identical in all
proximal tubular sub-segments.
Rate of flow out of urinary bladder KX (L/h)
DeFronzo et al., healthy baseline 0.63–1.20 Measured, raw data from an internal
database owned by Bristol-Myers
Squibb/AstraZeneca
DeFronzo et al., healthy after dapagliflozin 0.78–1.40
DeFronzo et al., T2DM baseline 0.54–1.24
DeFronzo et al., T2DM after dapagliflozin 0.80–1.20
Polidori et al., T2DM,
Mogensen healthy and diabetics
0.60 Assumed based on observations in
the DeFronzo et al., 2013
Wolf et al., diabetics 0.28 Wolf et al., 2009
GLUCOSE REABSORPTION
SGLT1 maximum reabsorption rate Vmax1 (mmol/h) 20.0 Model calibration (10% of 140mmol/h
in T2DM patients DeFronzo et al.,
2013 as starting point)
SGLT2 maximum reabsorption rate in diabetics Vmax2 (mmol/h) 110.0 Model calibration (90% of 140mmol/h
in T2DM patients DeFronzo et al.,
2013 as starting point)
SGLT2 maximum reabsorption rate in healthy Vmax2 (mmol/h) 93.5 Model calibration (100% of Vmax2 in
diabetes as starting point)
Glucose affinity for SGLT1 Km1 (mM) 0.5 Model calibration (1.8mM from
Hummel et al., 2011 as starting point)
Glucose affinity for SGLT2 Km2 (mM) 4.0 Model calibration (4.9mM from
Hummel et al., 2011 as starting point)
Sensitivity of renal glucose reabsorption and UGE to SGLT1 kinetics
(Vmax1 and Ki1)
The analysis of sensitivity of renal glucose reabsorption and UGE
to SGLT1 kinetics will help clarify these questions: (1) How strong
is the influence of an alteration of SGLT1 kinetics on renal glu-
cose reabsorption and UGE in the healthy state? (2) How strong
is the influence in the diabetic state? (3) From drug discovery per-
spective, without consideration of its effect on intestinal SGLT1,
will an SGLT1/2 dual inhibitor induce stronger glucosuria than a
highly selective SGLT2 inhibitor, e.g., dapagliflozin? The analysis
was conducted with simulations in a naive healthy subject and a
T2DM subject with or without SGLT2 inhibition under the SHC
procedure used by DeFronzo et al. (2013) with a target plasma
glucose range of 100–350mg/dL. With all other parameters held
constant, we first evaluated how a decrease in Vmax1 would affect
renal glucose reabsorption and UGE; and likewise, we then eval-
uated how changes in Km1, or Ki1 with the presence of SGLTs
inhibition, would affect renal glucose reabsorption and UGE.
SOFTWARE
Processing of the raw data from the DeFronzo et al. study (2013)
was conducted using S-PLUS 8.1 version 3.4 (TIBCO, Palo Alto,
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Table 3 | SGLT2 inhibitor-specific parameters.
Parameter Dapagliflozin Canagliflozin
Molecular weight
(MW, g/mole)
409 454
Free fraction in
plasma (fup)
0.07* 0.01 Devineni et al., 2013
Affinity for SGLT1
(Ki1, nM)
400 Hummel et al.,
2011
200 (half of dapagliflozin
Ki1 as per Grempler
et al., 2012)
Affinity for SGLT2
(Ki2, nM)
0.3 (model calibration,
6 nM from Hummel
et al., 2011 as starting
point)
0.6 (2-fold of dapagliflozin
Ki2 as per Grempler
et al., 2012)
*Reference: Bristol-Myers Squibb/AstraZeneca report (2010): Summary of clini-
cal pharmacology studies: Dapagliflozin (BMS-512148). BMS Document Control
Number 930047848.
CA) on a UNIX platform. Model development and simulations
were performed using BerkeleyMadonna version 8.3.18 (Berkeley
Madonna Inc., Berkeley, CA).
RESULTS
MODEL CALIBRATION USING DeFronzo et al. (2013)
The UGE data from DeFronzo et al. (2013) allowed estima-
tion of Vmax, glucose Km, and dapagliflozin Ki values for SGLTs
in the healthy subjects and T2DM patients. In the model, the
healthy and T2DM subjects were differentiated by their Vmax2
for describing the DeFronzo et al. conditions. The parame-
ter estimates are presented in Tables 2, 3. The model per-
formance is demonstrated in Figure 2. The model adequately
described the cumulative (Figures 2A,B) and step-wise UGE
data (Figures 2C,D) at baseline and in the first 4 h (where
the target plasma glucose escalated from 100 to 350mg/dL)
after dapagliflozin treatment. From 4.67 h onward (where the
target plasma glucose increased from 400 to 550mg/dL), the
model prediction of UGE in the dapagliflozin treated groups
was slightly lower than the observed. The glucose concentra-
tions in the tubular sub-segments PCT1-6 and PST1-3 in T2DM
patients at baseline and treated with dapagliflozin are illus-
trated in Figure S1. At baseline, the tubular glucose concen-
tration tapers along the proximal tubules with plasma glucose
level up to 23mM. With further increase in plasma glucose,
the tubular glucose level becomes more uniform as the reab-
sorption approaches saturation. After dapagliflozin treatment,
however, glucose is increasingly concentrated along the proximal
tubules.
MODEL EVALUATION
The calibratedmodel was evaluated for its predictive performance
relative to three separate clinical data sets (Mogensen, 1971; Wolf
et al., 2009; Polidori et al., 2013). The predictions are overlaid with
corresponding observations in Figure 3. The predictions agreed
well with the observed data, indicating that the model is plausi-
ble, has reasonable accuracy, and can be used for inference and
prediction.
SGLTs OPERATING CHARACTERISTICS FOR THE DeFronzo et al. (2013)
CONDITIONS
SGLTs relative contributions to renal glucose reabsorption
The model derived step-wise amount of glucose reabsorbed by
renal SGLT1 and SGLT2 in the healthy subjects at baseline and
after dapagliflozin treatment is shown in Figures 4A,B, and the
relative contributions of the two pathways at each step are in
Figures 4C,D. At near normal glycemic levels (∼100mg/dL) at
baseline (without SGLT2 inhibition), SGLT2 contributed to 90%
of total reabsorption and SGLT1 10%. The 90%/10% split became
80%/20% with plasma glucose escalated to over 200mg/dL. With
the presence of dapagliflozin, the contribution of SGLT2 declined
and SGLT1 became the more predominant reabsorption path-
way; the relative contributions varied with plasma dapagliflozin
concentration over time. Similar results were obtained in the
T2DM patients, for whom the relative contributions of SGLT1
and SGLT2 before and after dapagliflozin treatment are illustrated
in Figures 4E,F.
SGLTs operation efficiency
The calculated operation efficiency (defined as reabsorption
rate/Vmax × 100% for either SGLT1 or SGLT2) for both SGLTs
in the healthy subjects is plotted in Figure 5A. At the plasma
glucose level of ∼100mg/dL, SGLT2 and SGLT1 were operat-
ing at ∼40 and 20% of their respective Vmax. The operation
efficiency increased with plasma glucose (and thereby filtered glu-
cose load) for both SGLTs, with the slope for SGLT1 being much
steeper than for SGLT2. The operation efficiency at plasma glu-
cose ≥400mg/dL reached 97% for SGLT1 and 81% for SGLT2.
Even with plasma glucose as high as 550mg/dL, SGLT2 operated
at just 89% of its capacity. Dapagliflozin treatment lowered SGLT2
operation efficacy to as low as 10%, and drove SGLT1 operation to
over 90% of its capacity. Similar results were found in the T2DM
patients (Figure 5B).
SIMULATIONS AND EXPLORATIONS
Renal glucose reabsorption and UGE vs. loss-of-function mutation
of SGLTs
Simulations were conducted to establish quantitative relation-
ships between loss of function (i.e., reduction in Vmax) of SGLT2
or SGLT1 and renal glucose reabsorption as well as UGE in an
otherwise healthy subject with normoglycemia (plasma glucose
ranging from 80 to 125mg/dL with a time-weighted average of
90mg/dL). The simulation results for SGLT2 are in Figure 6A and
SGLT1 in Figure 6B. A 50% loss of function for SGLT2 caused
UGE of 4.5 g per day, and 100% of loss of function resulted in
79 g UGE per day. The total glucose reabsorption was lowered by
17, 32, and 49% for a 75, 87.5, and 100% loss of SGLT2 func-
tion, respectively. Loss of SGLT1 function caused much less severe
glucosuria, 1.2 g at 50% and 16 g at 100% of loss of function.
The total glucose reabsorption was reduced by only 10% with
complete loss of SGLT1 activity.
Sensitivity of renal glucose reabsorption and UGE to SGLT1 kinetics
In a naive healthy subject with a plasma glucose level
of ∼100mg/dL, the elimination of SGLT1 activity, either through
driving Vmax1 to zero or Km1 to infinity, inhibited renal glucose
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FIGURE 2 | Model description of cumulative (A,B) and step-wise (C,D)
urinary glucose excretion (UGE) in the healthy (A,C) and T2DM (B,D)
subjects at baseline and after 7 daily doses of 10mg dapagliflozin in the
DeFronzo et al. study (2013), where an stepwise hyperglycemic clamp
procedure was employed. The symbols represent observations and the
curves are model predictions. Pglu, plasma glucose concentration.
reabsorption by only 10%. This was consistent with the result
above for SGLT1 loss-of-function mutation (Figure 6B). In the
diabetic state with a mean plasma glucose level up to 250mg/dL,
simulations suggested a slightly stronger influence (up to 20%
lowering) on renal glucose reabsorption.
For simulations in the diabetic state with the presence
of SGLT2 inhibition, the inhibitor was assumed identical to
dapagliflozin, except that its Ki1 was allowed to change. The
sensitivity of UGE to Vmax1 at 10, 14, 17, and 20mmol/h (corre-
sponding to a 50, 30, 15, and 0% reduction in SGLT1 capacity)
is illustrated in Figure 7A. A mild to moderate, depending on
the glucose level, increase in UGE was expected with reduc-
tion in Vmax1. At the plasma glucose level of 150–250mg/dL,
roughly equivalent to the range of average levels in real-life T2DM
patients, a 30% reduction in Vmax1, presumed to be clinically well
tolerated (Abdul-Ghani et al., 2013), augmented glucosuria by up
to 30%. The sensitivity of UGE to Ki1 is depicted in Figure 7B.
The tested Ki1 values ranged from 6 to 10,000 nM. The 6 nM rep-
resented a 20× selectivity (similar to the SGLT1/2 dual inhibitor
LX4211 Zambrowicz et al., 2013) for SGLT2 (0.3 nM) vs. SGLT1
(6 nM) for an SGLTs inhibitor which is otherwise identical to
dapagliflozin. UGE was found to be insensitive to Ki1.
DISCUSSION
Highly selective and potent SGLT2 inhibitors, such as
dapagliflozin and canagliflozin, have demonstrated significant
and clinically meaningful effects on glycemic control in T2DM
patients. It has been puzzling that SGLT2 inhibitors inhibit
renal glucose reabsorption by only 30–50% clinically, despite
the overwhelming contribution of SGLT2 to renal glucose reab-
sorption (80–90%) under normal conditions. Several hypotheses
have been proposed for this apparently discrepant observation
(Haddish-Berhane et al., 2010; Maurer et al., 2011; Pfister et al.,
2011; Liu et al., 2012; Abdul-Ghani et al., 2013), and most of
them are focused on the compensatory effect of SGLT1. The
hypothesis of SGLT1 compensation has recently been confirmed
in mice (Rieg et al., 2014). However, due to the differences in
the experimental conditions in mice (Rieg et al., 2014) and in
clinical trials (Komoroski et al., 2009a; Devineni et al., 2013;
Heise et al., 2013; Washburn and Poucher, 2013) (see Table S1),
extrapolation of the Rieg et al. (2014) finding to the clinic is
not straightforward. As a whole, this situation indicates that,
despite tremendous advances in the basic biology of SGLTs and
pharmaceutical development targeting SGLT2, the roles of these
transporters in renal glucose reabsorption, especially in humans,
have yet to be clarified in a quantitative, mechanistic manner.
To this end, we developed a systems pharmacology model for
SGLT-mediated renal glucose reabsorption in humans with
or without pharmacological modulation of SGLT2 activity. In
general, this model adequately described four separate data sets
from different study settings (Mogensen, 1971; Wolf et al., 2009;
DeFronzo et al., 2013; Polidori et al., 2013) and replicated severe
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FIGURE 3 | Evaluation of model predictivity against three separate
clinical data sets. (A) Polidori et al. (2013) urinary glucose excretion (UGE)
data in T2DM subjects at baseline and after 8 daily doses of 100mg
canagliflozin. The symbols represent the observed data and the curves are
model predictions. (B) Wolf et al. (2009) renal glucose reabsorption rate in
T2DM patients who were subjected to a stepwise hyperglycemic clamp
procedure. (C) Mogensen (1971) renal glucose reabsorption rate in healthy
and diabetic subjects with plasma glucose levels elevated to over 650mg/dL.
glucosuria (79 g/day) in normoglycemic human subjects with
homozygous SLGT2 mutations (Santer et al., 2003).
The prediction of UGE at the plasma glucose level of
400mg/dL and higher in the subjects treated with dapagliflozin
was lower than the observed data from DeFronzo et al.,
(Figure 2). This possibly results from compensatory effects in
the renal tubules when glucose concentrations are drastically ele-
vated. Bank and Aynedjian (1990) proposed that high glucose
concentration in the proximal tubules would stimulate water
reabsorption in the proximal portion and enhance compensatory
water excretion in the more distal portion. In the DeFronzo et al.
study (2013), an increase in urine volume was observed with
escalation of plasma glucose level. This hydrodynamic change
in response to glucose level may interfere with tubular glucose
reabsorption. These processes, however, were not included in the
model. Nevertheless, the unsatisfactory performance at high glu-
cose levels (over 400mg/dL) is unlikely to hamper the utility of
the model because those glucose levels are irrelevant to most of
normal or even diabetic conditions. Overall, the performance of
the model suggests that the model is useful for mechanistically
evaluating the roles of SGLT1 and SGLT2 in renal glucose reab-
sorption, and for predicting clinical pharmacodynamics of SGLT2
inhibitors.
CHARACTERIZATION OF SGLTs OPERATION WITHOUT THE PRESENCE
OF SGLT2 INHIBITION
The Vmax values of SGLT1 and SGLT2 were estimated to be
20mmol/h and 94 (healthy)/110 (diabetic) mmol/h, respectively,
and the glucose Km values for SGLT1 and SGLT2 were estimated
to be 0.5 and 4mM, respectively. The sum of the Vmax val-
ues (i.e., total reabsorption capacity) and the two Km estimates
are similar to previously reported estimates (Mogensen, 1971;
Diez-Sampedro et al., 2001; Chao and Henry, 2010; Hummel
et al., 2011; DeFronzo et al., 2013). The Vmax2/Vmax1 ratio in
the healthy subject (4.7) is consistent with that in the rat (5.4)
(Yamaguchi et al., 2011). These estimates reinforce the concept of
SGLT1 being a high affinity, low capacity transporter and SGLT2
being a low affinity, high capacity transporter for renal glucose
reabsorption.
Under near normoglycemic conditions (average plasma glu-
cose ∼80–120mg/dL) in both healthy and diabetic subjects,
SGLT2 and SGLT1 are operating at about 40 and 20% of
their respective capacities, and contributing to 90 and 10%
of total glucose reabsorption, respectively. With the increase
in plasma glucose concentration, SGLT2 operation efficiency
steadily increases to near 90% of its capacity, whereas SGLT1
operation efficiency jumps sharply to over 80% of its capacity
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FIGURE 4 | Model calculated step-wise amount of glucose
reabsorbed (A,B) and relative contributions to the reabsorption
(C–F) by renal SGLT1 and SGLT2 at baseline and after
dapagliflozin treatment in healthy subjects and patients with
diabetes under the SHC procedure in DeFronzo et al. (2013).
(A,C) healthy, baseline; (B,D) healthy, after treatment; (E) patient,
baseline; and (F) patient, after treatment. Cp,dapa, total plasma
concentration of dapagliflozin.
and then steadily approaches to the maximum. The relative
contributions of 90%/10% gradually becomes 80%/20% for
SGLT2 and SGLT1 as plasma glucose rises. These results solidify
the current characterization of the relative contributions of the
two transporters to renal glucose reabsorptoin without the pres-
ence of SGLT2 inhibition (Chao andHenry, 2010; DeFronzo et al.,
2012).
CHARACTERIZATION OF SGLT’s OPERATION IN THE PRESENCE OF
SGLT2 INHIBITION
With the treatment of dapagliflozin at its clinical dose (10mg
QD), the majority of SGLT2 is occupied by dapagliflozin
molecules (occupancy up to 98% at the peak exposure). The total
activity of SGLT2 in a healthy or T2DM subject is suppressed
considerably, from ∼40% of operation efficiency without SGLT2
inhibition to only 10% with the treatment of dapagliflozin.
Consequently, the contribution of SGLT2 to renal glucose reab-
sorption declines from 80 to 90% at baseline to less than 50%
with SGLT2 inhibition. Meanwhile, the importance of SGLT1 to
renal glucose reabsorption jumps sharply. The operation effi-
ciency of SGLT1 reaches over 90%, up from 20% at baseline.
As a result, SGLT1 accounts for over 50% of renal reabsorption
when SGLT2 is inhibited, much higher than the 10–20% at
baseline.
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FIGURE 5 | Model derived operation efficiency (defined as
glucose reabsorption rate/Vmax × 100% for either SGLT1 or
SGLT2) for both SGLTs at baseline and after dapagliflozin
treatment in the healthy subjects (A) and patients with
diabetes (B) under the stepwise hyperglycemic clamp procedure
in DeFronzo et al. (2013).
FIGURE 6 | Simulation of the relationships between loss of function (i.e., reduction in Vmax) and renal glucose reabsorption (% filtered) as well as
urinary glucose excretion (UGE) for SGLT2 (A) and SGLT1 (B) in an otherwise healthy subject with normoglycemia.
THEORETICAL MAXIMUM INHIBITION OF RENAL GLUCOSE
REABSORPTION
The simulations of loss of function of SGLTs (reduction in Vmax)
vs. renal glucose reabsorption provide a clean relationship for
assessing the theoretical maximum inhibition of the reabsorption.
In a healthy subject under physiological conditions, an 87.5–
100% loss of SGLT2 function results in a 32–49% of inhibition of
renal glucose reabsorption. In a diabetic patient, the glucose reab-
sorption vs. loss of SGLT2 activity curve shifts downwards, i.e.,
somewhat greater inhibition of reabsorption. With a daily aver-
age plasma glucose level of 150mg/dL, a complete loss of SGLT2
activity lowers the reabsorption by 70%. This greater extent of
inhibition in diabetics is due to the up-regulated activity of SGLT2
in the disease state (Rahmoune et al., 2005).
The loss of SGLT1 function has only mild inhibitory effect on
renal glucose reabsorption. An entire loss of SGLT1 function leads
to only 10% of inhibition of glucose reabsorption in a normo-
glycemic healthy subject and up to 15% of inhibition in a diabetic
patient with a daily average plasma glucose level of 150mg/dL.
Our results of theoretical maximum inhibition of renal glu-
cose reabsorption due to loss of activity of SGLT1 or SGLT2 are in
general agreement with the findings in Sglt1/2 knock-out mice.
In Sglt2−/− mice the renal glucose reabsorption is reduced to
∼50% of that in wild-type mice at euglycemia, and is further
reduced with increase in filtered glucose load (Vallon et al., 2011).
The knock-out of Sglt1−/− in mice causes a 2–3% decrease in
total renal glucose reabsorption (Gorboulev et al., 2012; Powell
et al., 2013). The numerical discrepancy in the maximum influ-
ence of SGLT1 loss (2–3% in mice vs. 10% in humans) is yet to
be understood. It may reflect a real inter-species difference in the
contribution of SGLT1, a result secondary to inter-species differ-
ences in other physiological factors, or an inter-study variation as
well as random errors. Extension of our systems pharmacology
model to mice with appropriate physiological parameters could
shed light on this issue.
EXPLANATION TO THE PUZZLING MODERATE INHIBITION OF RENAL
GLUCOSE REABSORPTION BY POTENT SGLT2 INHIBITORS
Based on the modeling and simulations, it is likely that the
apparently moderate inhibition of renal glucose reabsorption
induced by potent SGLT2 inhibitors is a combined result of two
physiological determinants:
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FIGURE 7 | Sensitivity of urinary glucose excretion (UGE) to SGLT1
capacity (Vmax1) (A) and inhibitor affinity to SGLT1 (Ki1) (B) in a T2DM
patient subjected to the same study procedure as in DeFronzo et al.
(2013) with target plasma glucose from 100 to 350mg/dL with
increments of 50mg/dL. For the analysis on Vmax1, all other parameters
were held constant and Vmax1 was varied to 10, 14, 17, or 20mmole/h
(corresponding to a 50, 30, 15%, or 0% reduction of SGLT1 capacity). For the
analysis on Ki1, the Ki1 value of an SGLT2 inhibitor which was otherwise
identical to dapagliflozin was varied from 6 to 10,000 nM, representing a
selectivity for SGLT2 from 20× to 33,333×.
(1) SGLT1 compensation: Based on the localization and physio-
logical characteristics of SGLT1 and SGLT2 in the kidney, it
has been suspected that, with the buildup of glucose along
the proximal tubules, SGLT1 will operate more intensely,
and hence offset to certain degree the effect of SGLT2 inhi-
bition (Haddish-Berhane et al., 2010; Maurer et al., 2011;
Abdul-Ghani et al., 2013). This concept is supported by
the modeling and simulation results discussed above. After
dapagliflozin treatment in humans, SGLT1 operates at its
near maximum capacity and becomes the predominant path-
way for glucose reabsorption. Nevertheless, the theoretical
maximum inhibition of renal glucose reabsorption is 50–
70% in the healthy and T2DM subjects, higher than the
observed 30–50%. This disagreement suggests that, besides
SGLT1 compensation, there should be additional explana-
tion(s).
(2) Residual activity of SGLT2: The modeling identified the resid-
ual SGLT2 activity to be an additional explanation. Although
SGLT2 inhibitors, such as dapagliflozin, canagliflozin, at clin-
ical doses do occupy the majority of SGLT2 and severely sup-
press SGLT2 activity, they do not completely eliminate SGLT2
activity. This is readily deduced from Equation 2: when the
luminal glucose level in PCT rises to several fold higher
than Km2 resulting from SGLT2 inhibition, the inhibitor
exposure has to be several hundred fold of Ki2, beyond
the clinically feasible range, in order to drive the SGLT2-
mediated reabsorption rate to near zero. After a treatment
with dapagliflozin at 10mg, there remains at least ∼8–10%
of residual SGLT2 activity, i.e., 7–11mmol/h of reabsorption
rate, in the healthy and diabetics. This residual activity is still
sizeable compared with SGLT1 capacity of 20mmol/h.
Rieg et al. (2014) recently observed a 56% of lowering of renal
glucose reabsorption in mice with complete SGLT2 inhibition,
and an entire demolition of reabsorption in mice lacking both
SGLT1 and SGLT2. This result confirms the hypothesis of SGLT1
compensation. The extrapolation of this finding to the clinic,
however, is complicated by the differences in the experimental
conditions in the Rieg et al. (2014) and clinical trials (Komoroski
et al., 2009a,b; Devineni et al., 2013; Heise et al., 2013) (see Table
S1). While a complete blockage of SGLT2 is likely in the Rieg
et al. (2014) with drastically elevated concentration (free plasma
concentration at least 10–15-fold higher than in vitro IC50) of
empagliflozin over the duration of 30min for UGE collection, in
the clinical trials with once daily dosing, it is unlikely to maintain
a 100% blockage of SGLT2 throughout a day over which luminal
drug concentrations decline and 24 h UGE is collected. Thus, to
explain the apparently moderate inhibition of renal glucose reab-
sorption by potent SGLT2 inhibitors in the clinic, the residual
activity of SGLT2 should not be overlooked.
It is worth pointing out that dapagliflozin does severely sup-
press SGLT2 activity at its approved dose of 10mg/day, as demon-
strated by the simulations (Figure S2) at steady state in a hypo-
thetical healthy subject with a constant plasma glucose level of
100mg/dL treated with dapagliflozin at various doses. The SGLT2
activity decreases with increase in dose; from 20mg onward, there
is mild further decrease in SGLT2 activity. For SGLT1, its activity
is nearly saturated at 10mg. These results seem to be consis-
tent with previous clinical observations that the UGE effect of
dapagliflozin saturates at 20mg (Komoroski et al., 2009a).
EFFECT OF AN SGLT1/2 DUAL INHIBITOR ON GLUCOSURIA IN
COMPARISONWITH A SELECTIVE SGLT2 INHIBITOR
It has been a question whether or not an SGLT1/2 dual inhibitor
would induce greater glucosuria than a highly selective SGLT2
inhibitor (Chao and Henry, 2010; Abdul-Ghani et al., 2013).
Abdul-Ghani et al. (2013) hypothesized that glucosuria induced
by an SGLT2 inhibitor with a moderate selectivity over SGLT1
(e.g., capable of inhibiting SGLT1 activity by 30%) may be sub-
stantially greater than with a highly selective SGLT2 inhibitor.
Using our model, we examined the sensitivity of UGE to Vmax1
and Ki1 in humans. We found that UGE was mildly to moder-
ately sensitive to Vmax1 but not Ki1 in the presumably clinically
tolerable ranges. The insensitivity to Ki1 is implied by Equation
(2). With a treatment of 10mg dapagliflozin, the glucose con-
centration in the PST rises to at least 20-fold of Km1. In order
to moderately suppress SGLT1-mediated reabsorption through
competitive inhibition, the luminal inhibitor exposure has to
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reach tens of fold of Ki1, a level that cannot be safely achieved
in humans.
Therefore, without the consideration of its effect on intesti-
nal SGLT1, whether or not a dual inhibitor will induce stronger
glucosuria than a selective SGLT2 inhibitor is dependent on
the mode of interaction between the dual inhibitor and SGLT1.
A competitive inhibition of SGLT1 is unlikely to afford the
dual inhibitor augmented effect on glucosuria. Other modes of
inhibitions (non-competitive or uncompetitive) that attenuate
Vmax1 may augment glucosuria mildly to moderately with a dual
inhibitor.
In summary, to clarify mechanistically and quantitatively the
operating characteristics of SGLT1 and SGLT2 in renal glucose
reabsorption, we developed a systems pharmacology model with
emphasis on renal glucose filtration, reabsorption, and transfer
along the proximal tubules with or without SGLT1/2 inhibition.
The model was calibrated using DeFronzo et al. (2013) and eval-
uated against three other data sets (Mogensen, 1971; Wolf et al.,
2009; Polidori et al., 2013). Simulations using this model pro-
vided insights into the operating characteristics of SGLTs under
normo- and hyperglycemic conditions in the healthy and diabetic
state with or without SGLT2 inhibition. The simulations solidi-
fied the current concept of the relative contributions of SGLT1/2
to renal glucose reabsorption without the presence of SGLT2
inhibition. Moreover, the simulations elucidated quantitatively
the operating characteristics of SGLTs when SGLT2 is inhibited.
Further simulations clarified the relationships between SGLT1/2
capacity and renal glucose reabsorption in humans. Based on our
modeling and simulations, we propose that the apparent mod-
erate inhibition of renal glucose reabsorption observed clinically
with SGLT2 inhibitors is a combined result of two physiological
determinants, SGLT1 compensation and residual SGLT2 activ-
ity. This model will be valuable in mapping SGLT2 genotype
to its functionality, and in predicting, through the incorpora-
tion of a plasma glucose-insulin model, the efficacy of an SGLT2
inhibitor in patients with diabetes, especially pediatric patients
and patients with type 1 diabetes, for whom clinical data remain
scarce.
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